- 全部删除
 
您的购物车当前为空
PKI-166是一种可口服的EGF-R 酪氨酸激酶抑制剂(IC50 : 0.7 nM),具有有效性和选择性。PKI-166能有效抑制包括胰腺癌在内的多种人类癌细胞的生长和转移。

PKI-166是一种可口服的EGF-R 酪氨酸激酶抑制剂(IC50 : 0.7 nM),具有有效性和选择性。PKI-166能有效抑制包括胰腺癌在内的多种人类癌细胞的生长和转移。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 347  | In stock | |
| 5 mg | ¥ 738  | In stock | |
| 10 mg | ¥ 1,110  | In stock | |
| 25 mg | ¥ 1,980  | In stock | |
| 50 mg | ¥ 2,980  | In stock | |
| 100 mg | ¥ 4,120  | In stock | |
| 200 mg | ¥ 5,560  | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 816  | In stock | 
PKI-166 相关产品
| 产品描述 | PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.  | 
| 靶点活性 |  EGFR tyrosine kinase:0.7 nM  | 
| 体外活性 | PKI-166(0–0.5 μM;1小时)预处理可以抑制人类胰腺癌细胞中EGFR的自磷酸化。此外,PKI-166(0.03μM;6天)能增强由吉西他滨介导的细胞毒性。[1]  | 
| 体内活性 | PKI-166(100 mg/kg;口服;每天一次;自异种移植后第7天至第35天)能够抑制胰腺癌的生长。[1]  | 
| 分子量 | 330.38 | 
| 分子式 | C20H18N4O | 
| CAS No. | 187724-61-4 | 
| Smiles | C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1 | 
| 密度 | 1.324 g/cm3 (Predicted) | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 27.5 mg/mL (83.24 mM), Sonication is recommended.   | ||||||||||||||||||||||||||||||
溶液配制表  | |||||||||||||||||||||||||||||||
DMSO 
  | |||||||||||||||||||||||||||||||
评论内容